Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"Emifarma","sponsor":"Mangoceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"MEXICO","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Emifarma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Emifarma will be responsible for the initial stages of development and testing of the Company’s Mango ED products, including Mango ED, a combination of Tadalafil, Oxytocin, and L-Arginine, intended for the Mexican and Latin American markets.

            Lead Product(s): Tadalafil,Oxytocin,L-Arginine

            Therapeutic Area: Psychiatry/Psychology Product Name: Mango ED

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Mangoceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 12, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY